Alder Biopharmaceuticals - Top 20 VC deals of 2008

Alder Biosciences, Fiercebiotech's top venture capital deals of 2008Company: Alder Biopharmaceuticals
Based: Bothell, WA
Amount: $40.2 million

Investors: TPG Growth, Delphi Ventures, Ventures West Management, Sevin Rosen Funds, H.I.G. Capital, WRF Capital

Scoop: Alder started 2008 on a good foot. The company secured a $40.2 million third round in January to support development of its lead antibody therapeutic ALD518 through multiple proof-of-concept trials. Unlike many other biopharma companies, Alder actually boosted its staff from 34 to about 50. The new employees are working on antibody manufacturing and clinical development.

Alder Biopharmaceuticals - Top 20 VC deals of 2008

Suggested Articles

Rapt Therapeutics filed to raise up to $75 million in its IPO after postponing an earlier attempt to raise $86 million in August.

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.